Moh’d Khushman
University of South Alabama
74 Papers
73 Citations
Moh’d Khushman is an academic researcher from University of South Alabama. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 12, co-authored 41 publications. Previous affiliations of Moh’d Khushman include Henry Ford Hospital & University of Miami.
Chat about Author
Papers
Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications.
Girijesh Kumar Patel,Mohammad Aslam Khan,Haseeb Zubair,Sanjeev K. Srivastava,Moh’d Khushman,Seema Singh,Ajay P. Singh +6 more
TL;DR: The efficacy of four kits from Invitrogen, 101Bio, Wako and iZON along with conventional ultracentrifugation-based method for exosome yield, purity and quality are compared to serve as a guide to choose and further optimize exosomal isolation methods for their desired downstream applications.
Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
Girijesh Kumar Patel,Mohammad Aslam Khan,Arun Bhardwaj,Sanjeev K. Srivastava,Haseeb Zubair,Mary C. Patton,Seema Singh,Moh’d Khushman,Ajay P. Singh +8 more
TL;DR: A novel role of exosomes in mediating the acquired chemoresistance of PC cells is established and either the functional suppression of miR-155 or restoration of DCK led to marked abrogation of Gem-Exo-mediatedChemoresistance.
Molecular profile of BRCA-mutated biliary tract cancers
Gilbert Spizzo,Alberto Puccini,Joanne Xiu,Richard M. Goldberg,Axel Grothey,Anthony F. Shields,Sukeshi Patel Arora,Moh’d Khushman,Mohamed E. Salem,Francesca Battaglin,Yasmine Baca,Wafik S. El-Deiry,Philip A. Philip,Madiha Nassem,Michael J. Hall,John L. Marshall,Florian Kocher,Arno Amann,Dominik Wolf,W. Michael Korn,Heinz-Josef Lenz,Andreas Seeber +21 more
- 01 Jun 2020
TL;DR: BRCA mutations are found in a subgroup of patients with BTC and are characterised by a distinct molecular profile, providing a rationale testing poly(ADP-ribose)polymeraseinhibitors and other targeted therapies in patients with BRCA-mutant BTC.
82
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.
Mohammad Aslam Khan,Shafquat Azim,Haseeb Zubair,Arun Bhardwaj,Girijesh Kumar Patel,Moh’d Khushman,Seema Singh,Ajay P. Singh +7 more
TL;DR: This review article provides up-to-date information on the genetic and epigenetic changes that occur during the initiation and progression of PC and their functional involvement in the pathogenic processes.
66
Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma.
Philip Phillips,Ibrahim Azar,Joanne Xiu,Michael N. Hall,Andrew Eugene Hendifar,Emil Lou,Jimmy Hwang,Jun Gong,Rebecca Feldman,Michelle S. Ellis,Phillip Stafford,David Spetzler,Moh’d Khushman,Davendra Sohal,A. Craig Lockhart,Benjamin A. Weinberg,Wafik S. El-Deiry,John Marshall,Anthony F. Shields,W. Michael Korn +19 more
TL;DR: Real-world evidence reveals a survival advantage of KRAS-WT patients in overall cohorts as well as in patients treated with gemcitabine/nab-paclitaxel or 5FU/oxaliplatin.
60